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Evaluation of vaccine efﬁcacy for protection against colonisation (VEcol) with Streptococcus pneumoniae
andother bacterial pathogens is oftenbasedona cross-sectional studydesign, inwhichonly onenasopha-
ryngeal sample is obtained per study subject. Here we investigate the feasibility of this study design
by investigating a number of practical design problems. Speciﬁc questions are related to the timing of
colonisation measurement with respect to the time of vaccination, the adjustment for the within-hosteywords:
ultiple colonisation
asopharyngeal colonisation
ample size
neumococcus
replacement of vaccine-type colonisation by the non-vaccine type pneumococci, and the impact of mul-
tiple serotype colonisation on VEcol estimation. We also discuss the issue of choosing the control vaccine,
including comparison of two active pneumococcal vaccines, as well as the sample size and the statistical
power of colonisation endpoint trials. In addition, the statistical design with the speciﬁc aim to include
information about VEcol in the licensure process of new pneumococcal vaccine products is discussed.accine efﬁcacy
. Introduction
Evaluation of vaccine efﬁcacy for protection against coloni-
ation (VEcol) with Streptococcus pneumoniae and other bacterial
athogens is oftenbasedona cross-sectional studydesign, inwhich
nly one nasopharyngeal sample is obtained per study subject. The
ccompanying article in this volume [1] summarises the key ingre-
ients of VEcol estimation from such cross-sectional data, including
he choice of vaccine efﬁcacy parameter and the appropriate
lassiﬁcation of samples according to vaccine- and non-vaccine-
ype colonisation. VEcol is used as an umbrella concept for a number
f different vaccine efﬁcacy parameters. The parameters of most
nterest are vaccine efﬁcacy against acquisition of carriage (VEacq),
Abbreviations: PCV, pneumococcal conjugate vaccine; VEcol , vaccine efﬁcacy
gainst colonisation; VEacq , vaccine efﬁcacy against acquisition of colonisation; VET ,
ombined vaccine efﬁcacy against acquisition and duration of colonisation; VT, vac-
ine (sero)type(s); NVT, non-vaccine (sero)type(s).
∗ Corresponding author at: Department of Vaccination and Immune Protection,
.O. Box30, FI-00271Helsinki, Finland. Tel.: +358295248874; fax: +358295248675.
E-mail address: kari.auranen@thl.ﬁ (K. Auranen).
1 For the Pneumococcal Carriage Group (PneumoCarr). See Appendix A.
264-410X © 2013 Elsevier Ltd.
ttp://dx.doi.org/10.1016/j.vaccine.2013.06.105
Open access under CC BY license.© 2013 Elsevier Ltd.
vaccine efﬁcacy against duration of carriage (VEdur), and the com-
bined efﬁcacy against acquisition and duration (VET; cf. Table 1 and
Fig. 1 in [1]).
In practice, a number of other questions need to be answered
in the design phase of a study prior to data collection. This arti-
cle concentrates on practical questions when estimation of VEcol
is based on only one sample per study subject. We explore the
inﬂuence of the time-lag between vaccination and sampling on
estimation of vaccine efﬁcacy. We also consider the implications
of multiple serotype carriage. We discuss the choice of the control
vaccine and the sample size, respectively, special attention paid to
non-inferiority trials, in which an active control vaccine is used.
Finally, we discuss some special issues for future work. The discus-
sion is generic and applicable to studies of pneumococcal conjugate
vaccines (PCV), newer pneumococcal vaccine formulations with
protein orwhole-cell antigens and to similar vaccines against other
pathogens.
Open access under CC BY license.2. Timing of the sampling in relation to vaccination
An important factor affecting VEcol estimation is the sampling
time with regard to the vaccination of an individual. Firstly, it takes
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ome time for the immune response to induce protective immunity
n an individual after vaccination. Speciﬁcally, in infants and tod-
lers, studies on the kinetics of antibody concentration have shown
hat it takes 2–4 weeks following PCV vaccination before the peak
ntibody concentration is obtained.
Secondly, vaccination interferes with the prevalence and
erotype distribution of colonisation in the vaccinated group. This
ransition phase needs to be taken into account to avoid bias in the
stimates of VEcol when based on only one sample per study sub-
ect. Here, biasmeans adifference between the true efﬁcacy and the
ean of efﬁcacy estimates in an idealised sequence of studies. The
agnitude of bias depends on the time since vaccination or, more
ccurately, on the time since the protective effect of vaccination
as taken effect. By using simulated studies, we investigated how
he time of sampling affects VEcol estimation under two scenarios:
1) A vaccine trial in infants, with very low prevalence of colonisa-
tion at vaccination (Fig. 1, left panel);
2) A vaccine trial in children, with the steady-state pre-
vaccination colonisation (Fig. 1, right panel).
he ﬁrst scenario represents a trial in infants in a setting where
he overall prevalence of carriage at vaccination is close to zero.
he second scenario represents a trial in young children in a set-
ing where the serotype distribution has reached or is close to the
tationary phase. In practice, trials can usually be assumed to lie
omewhere between these two extremes.
Fig. 1 shows the mean of estimates of vaccine efﬁcacy against
neumococcal vaccine-type acquisition (VEacq) as a function of the
ime since immune-response, when estimation is based on cross-
ectional data (cf. [1]) and assuming that vaccinationdoesnot affect
uration of colonisation. The main factor affecting how the bias in
he estimated vaccine efﬁcacy becomes negligible is the prevalence
f colonisation at the time of vaccination. When the prevalence
s close to 0 (left-hand panel), the mean of VEacq estimates from
ross-sectional data closely approximate the true VEacq as long as
he samples are collected 2–3 months after vaccination. When the
revalence of colonisation is higher (right-hand panel), the bias is
nitially clearly negative and becomes relatively small only after
everal months since vaccination.
As a rule-of-thumb for both scenarios, the time from vaccina-
ion until nasopharyngeal sampling is determined by the rate of
learance rather than the rate of pneumococcal acquisition. This is
hown by comparison between the “high” vs. “moderate” scenarios
or overall acquisition in Fig. 1. Under both scenarios, colonisation
hould be sampled only after at least twice the average dura-
ion of a carriage episode has passed since the immune-response.
n the example, the mean duration was approximately 2 months
nd the sampling should thus occur 4 months after the immuno-
esponse or somewhat later. The results for the combined vaccine
fﬁcacy against acquisition and duration (VET) were similar (data
ot shown). Apart from the requirement of approximate steady-
tate at the time of sampling, there are other factors that rather
avour early measurement of colonisation (e.g. the possibility of
aning immunity or changes in exposure with age and/or season).
n addition to bias, the precision of estimation and sample size (cf.
ection 5) need to be considered. In general, the precision was poor
n the ﬁrst 2 months, in particular with low individual prevalence
nd moderate rate of pneumococcal acquisition (data not shown).
Also serotype-speciﬁc estimates can be obtained from a cross-
ectional study (cf. Section 4 in [1]). In general, their estimation
erforms similarly to the aggregate (i.e., all vaccine-type) efﬁcacy.
or serotypes with very low prevalence, however, the negative bias
n the efﬁcacy estimates is obviously somewhat bigger unless the
ample size is very large.32 (2014) 159–164
3. Multiple colonisation and estimation of vaccine efﬁcacy
The sensitivity of detecting pneumococcal colonisation depends
on the technique of specimen sampling and handling, and the
methodology to culture, identify and serotype pneumococci [2].
The current standard, which is based on using a single nasopha-
ryngeal swab to measure the prevalence of pneumococcal carriage,
is simple and rapid. The sensitivity of a single swab to detect and
identify the dominant pneumococcal serotype is high, being in the
range of 85–100% [2–4].
A key challenge to nasopharyngeal sampling remains the iden-
tiﬁcation of multiple serotypes simultaneously colonising the
nasopharynx. Simultaneous colonisationwithmore thanonepneu-
mococcal serotype (or strain) is relatively common, particularly in
areas with a high burden of pneumococcal carriage and disease.
When more sensitive methods are applied, such as serotyping of
many colonies, molecular methods such as PCR and/or adding a
culture-enrichment step, the rate of multiple serotype carriage is
approximately 20–50% [5–7].
Carriage thus often consists of a major (or dominant) serotype
andoneormoreminor serotypepopulations. Commonly, themajor
serotype accounts for approximately 70–90% of the total pneumo-
coccal content [5,8]. It is conceivable that some serotypes, such
as the ‘epidemic’ serotypes 1 and 5 that are rarely detected in
carriage but often in disease,maybe found asminor serotypepopu-
lations. Interestingly, it seems that some serotypes are found less
frequently in co-colonisation than would be expected by chance
alone [8,9].
Multiple colonisation may pose a problem for the estimation of
vaccine efﬁcacy against colonisation. In principle, the deﬁnitions of
VET and VEacq take into account the possibility of double coloni-
sation and could be expanded to address multiple colonisation
in general. In practice, however, insensitive detection of multi-
ple serotype carriage creates a measurement problem, because the
classiﬁcation of samples into the target and reference states of
colonisation according to the vaccine/non-vaccine isolates depends
on our ability to identify individual serotypes in nasopharyngeal
samples (cf. Section 3 in [1]).
Simulation studies show that under certain conditions the
impact of insensitive detection of multiple colonisation does not
bias the estimation of VEcol [10]. These conditions are met if mul-
tiple colonisation among colonised individuals is not common or
there is no systematic propensity for ﬁnding certain serotypes over
others, in addition to that caused by their acquisition rates. The
latter assumption is true, if the serotype distributions among the
major and minor populations are similar and the detection method
does not favour some serotypes over others. If minority types differ
in their composition, i.e. containing more rare types as suggested
by Brugger et al. [9], estimation of VEcol for these types can pos-
sibly be based on colonisation among cases of disease (Section
5).
Finally, it can be argued that in most cases vaccine efﬁcacy esti-
mates should be based on the dominant serotype, because it is the
serotypemost likely to be transmitted. If the density of colonisation
is associated with the disease risk as suggested by a recent study
among adult pneumonia patients [11], VEcol against the dominant
serotypes would logically be the endpoint directly predicting risk
of disease. Nevertheless, the questions about replacement coloni-
sation and epidemic serotypes residing as minor populations in the
nasopharynx may require special attention.4. The control vaccine
The choice of the control vaccine is conditional on the status
of PCV use in the population where the trial is to be carried out.
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Fig. 1. The impact of the time of measurement on estimates of vaccine efﬁcacy against pneumococcal acquisition from a cross-sectional study. The ﬁgure presents the mean
estimate of vaccine efﬁcacy in an ideal sequence of vaccine trials. Left panel: All individuals are uncolonised at the time of vaccination. Right panel: The individuals start from
the steady-state distribution at the time of vaccination. In both panels, the results are based on 300 simulated data sets, each with 1000 vaccinees and 1000 controls. The
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cquisition (see the Appendix in [1] for more details). The true values of the aggreg
orizontal lines (approximately 60%).
he status of the PCV programme can be divided into four differ-
nt stages: (1) No recommendation for PCV introduction has been
aken; (2) Ofﬁcial decision to introduce PCV has been taken, but
t has not been implemented yet; (3) PCV has been introduced
ecently; or (4) PCV has been introduced quite some time ago. If
CV has not been recommended, the control group could be given
lacebo, provided it is ethically acceptable in the trial population.
f a placebo is not acceptable, a non-pneumococcal control vac-
ine should be sought. Preferably, it should be a vaccine already
egistered, rather than an investigational one. Optimally, the non-
neumococcal control vaccine should not impact the microbiota of
he upper respiratory tract as interactions between different bacte-
ial occupying the sameecological niche have been observed [12]. If
he use of a non-pneumococcal control vaccine is not an acceptable
pproach, the presently used (licensed) pneumococcal vaccinemay
erve as an active control. The main points in choosing the control
accine are summarised in Table 1.
. Sample size and the power of VEcol studiesWe consider the statistical power of VEcol studies for show-
ng either the efﬁcacy against all vaccine-type (VT) acquisition
r serotype-speciﬁc efﬁcacy against acquisition of individual
able 1
hoice of the control vaccine. Factors affecting the choice of the control vaccine and its im
Country’s stand on PCV
No recommendation to
introduce PCV yet
Decision to in
PCV; not yet
implemented
Ecology of Pnc Undisturbed Undisturbed
Reliability of VEcol estimation VE reliable VE reliable
Control vaccinec
Placebo May be ethically
complicated
Ethically com
Active pneumococcal control Can be used Can be used
a vaccine-types (VT).
b non-vaccine types (NVT).
c If an active antigen is to be used as control vaccine, it should not impact the microbio
aintain blinding. Investigational new vaccines, the impact of which on upper respirator
f possible.lonisation corresponding to either a high or moderate rate of overall pneumococcal
cacy against the vaccine types depend on the acquisition rates and are marked by
serotypes. The estimation method is based on a cross-sectional
sample under the assumption of no efﬁcacy on duration [1,10].
Basedon thescenariospresented in theprevious section,wediscuss
the following two alternatives regarding the control vaccine:
A) A control vaccine with known zero (biological) efﬁcacy against
the pneumococcal colonisation endpoint;
(B) A pneumococcal vaccine, with previously shown efﬁcacy
against the colonisation endpoint.
With an active control vaccine (alternative B), special consideration
needs to be given to the choice of the reference and target states of
colonisation, in particular if the two vaccines to be compared have
different compositions (i.e. numbers and/or selection of serotypes).
Controlled trials. Alternative A leads to a standard superiority
trialwith a non-active control. Here, the statistical power is deﬁned
as the probability for the lower bound of the conﬁdence interval
for VEacq to exceed 0 under the alternative hypothesis, i.e. when
VEacq is at least D (the smallest meaningful efﬁcacy). The choice of
D can be based on the herd immunity threshold, that is, a level of
direct protection against colonisation which would induce signif-
icant indirect protection in the population. Theoretical modelling
suggests that even 50% efﬁcacy (VEacq) could be enough for herd
pact on the feasibility of VEcol estimation.
troduce PCV recently introduced PCV introduced some
years ago
Exposure to VTa
colonisation may be
reduced
Exposure to VT
colonisation reduced,
replacement by NVTb
increased
VE may be biased VE unreliable
plicated Not acceptable Not acceptable
Can be used Can be used
ta of the upper respiratory tract in any way. It also should look like PCV in order to
y tract (URT) microbiota is not known, complicate the trial and should be avoided
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Fig. 2. Statistical power to show vaccine efﬁcacy against all vaccine-type colonisation. The power is presented as function of the number of individuals per study group
(horizontal axis: from 100 to 900) and the hypothesised vaccine efﬁcacy against the vaccine types (i.e. the smallest meaningful efﬁcacy D; vertical axis: from 10% to 90%)
under alternative A (superiority trial, see text). The type I error is set at 10% and two-sided 90% conﬁdence intervals are used. The results in this ﬁgure are based on a simulated
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he high and moderate overall rates of pneumococcal acquisition, with 86% and 52
erotype-speciﬁc efﬁcacies were allowed to be heterogeneous retaining the same a
mmunity, if the coverage of vaccination in the infant programme
s high [13].
Fig. 2 presents the power of a controlled study under scenario
for different values of the sample size (number of individuals
er study group) and the hypothesised efﬁcacy (D). For example,
group size of 300 is enough to obtain 80% power, if the vac-
ine efﬁcacy against vaccine-type acquisition is 50%. The results
re essentially similar under high (left panel) or moderate (right
anel) overall rate of pneumococcal acquisition.
Head-to-head trials.Under alternative B, the investigational vac-
ine’s effect is measured against an active pneumococcal vaccine.
he hazard rate ratio (investigational vs. active control) for the
elect set of target serotypes can be estimated from a cross-
ectional study with appropriate modiﬁcations to the method
eviewed in the accompanying article (Section 4 in [1]). In par-
icular, the reference set of colonisation states should exclude all
erotypes included in either of the two vaccines.
The target set of serotypes can be chosen in different ways,
epending on the question and purpose of the study:
(a) The vaccines are compared with regard to serotypes common
to both vaccines: the target set includes the common serotypes
only.
b) The vaccines are compared with regard to their own serotype
selection: the target sets may be different for the two vaccines.
If they are the same, this comparison reduces to (a).
(c) The vaccines are compared with regard to the union set of all
vaccine serotypes included in either vaccine: the common tar-
get set includes all serotypes included in either or both of the
two vaccines.
d) Vaccine efﬁcacy is considered for serotypes not included in the
other vaccine.
he statistical analysis under choices (a)–(c) can be approached as
non-inferiority trial. By contrast, the comparison regarding any
f the non-common serotypes in alternative (d) can be approached
s a superiority trial, in which the other vaccine is treated as an
nactive control. Also in this case, all vaccine types included ineither
f the two vaccines should be excluded from the reference set.
In the non-inferiority settings, the statistical power is deﬁned
s the probability for the lower bound of the conﬁdence interval
or the relative efﬁcacy (investigational vs. active control) to be
arger than a pre-chosen non-inferiority margin. Equivalently, the
argin deﬁnes an upper bound for the rate of overall target-type
cquisition for the investigational vaccine (see Appendix B).in [1] for details in the model speciﬁcation). The left and right panels correspond to
alence of pneumococcal colonisation, respectively. The power did not differ when
ate-level efﬁcacy against all vaccine types (data not shown).
In general, there are several aspects to be considered when
specifying non-inferiority margins [14]. For vaccine licensure, a
natural argument follows from the requirement to show vaccine
efﬁcacy against colonisation as high as to induce herd immunity
if the vaccine were used in large scale. If the active control vac-
cine is hypothesised to have at least 50% efﬁcacy (VEacq) against
overall target-type acquisition, the investigational vaccine can be
allowed to have 100% smaller efﬁcacy. A margin of  =0.2 may be
reasonable still to induce herd immunity. For example, if VEacq of
50% is considered for the active control vaccine, the power is calcu-
lated with 40% efﬁcacy for the investigational vaccine. The margin
for the efﬁcacies does not uniquely determine the margin for the
relative efﬁcacy. However, it can be shown that in the range in
which VEacq ≥0.5 for the active control vaccine, the margin of the
hazard ratio is approximated by −. If the efﬁcacy of the active con-
trol is clearly >50%, a wider margin can be allowed (see Appendix
B for more details).
Fig. 3 presents the power of a non-inferiority study for different
values of the sample size (number of individuals per study group)
and the vaccine efﬁcacy of the investigational vaccine, assuming
50%efﬁcacy for the activepneumococcal control vaccine andamar-
gin  =0.2. The analysis is based on alternative (a), i.e. on comparing
the rates of acquisition for the target set of serotypes common to
both vaccines. For instance, to obtain 80% power requires a group
size of 500 or more if the efﬁcacy of the investigational vaccine is as
high as 60% under scenario of the moderate overall rate of acquisi-
tion. If the investigational vaccine has only about 50% efﬁcacy, the
sample size needs to be very large for a high power.
Smaller sample sizes or less strict requirements on the efﬁ-
cacy of the investigational vaccine are needed if comparisons are
made against the union set of target serotypes (alternative (c)).
This might be a viable option in case of investigational vaccines
with a very large target set, such as the novel pneumococcal
vaccine formulations based on protein or whole-cell antigens.
Of note, the sample sizes are clearly smaller also under alterna-
tive (d), in which efﬁcacy for non-common (“new”) serotypes is
estimated.
6. Special issues and future work
Some pneumococcal serotypes are only rarely found in car-
riage despite causing a signiﬁcant proportion of disease. This is
particularly true for the invasive disease outcomes with so called
‘epidemic’ types (e.g. 1 and 5), since they are carried either very
brieﬂy or as minor populations in the nasopharynx. One possible
approach in such a case is to conduct a colonisation study in
K. Auranen et al. / Vaccine 32 (2014) 159–164 163
Fig. 3. Statistical power to show non-inferiority of an investigational vaccine. The power is presented as function of the number of individuals per study group (horizontal
axis: from 100 to 900) and the hypothesised vaccine efﬁcacy of the investigational vaccine (vertical axis: from 10% to 90%) under alternative B (non-inferiority trial, see text)
and considering acquisition of the common serotypes in the two vaccines (alternative (a), see text). The presented power is based on a simulated vaccine trialwith 9 serotypes,
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accine types is 50% for the active control vaccine. The type I error is set at 10% and
argin  for the relative efﬁcacy is set at 20% (see text). The left and right panels co
neumonia patients to estimate VEcol. It would then be based
n rates of acquisition weighted according to the case-to-carrier
atios (i.e. probabilities of disease per episode of carriage) for each
f the target serotypes, reﬂecting more directly the distribution
f serotypes causing disease. The set of reference states of coloni-
ation should again exclude any states with VT colonisation (cf.
ection 4 in [1]). Apart from the fact that the uncolonised study
ubjects can be included in the reference set of the analysis, this
tudy design is equivalent to the indirect cohort method.
The indirect effects of large-scale vaccination with current PCVs
n the whole population follow after a relatively short time-lag.
sually such changes are seen in VT colonisation. Therefore, it may
e of concern that data collected in vaccine studies conducted in
estrictedareasmaybeaffectedby indirectprotection, thus compli-
ating the interpretation of any estimates of direct vaccine efﬁcacy.
heoretical results based on a simple VT/NVT split indicate that
revalence-based estimates of vaccine efﬁcacy are less prone to
ias when indirect protection occurs simultaneously in vaccinees
nd controls [15].
One problem requiring further investigation is the possibility
f an interaction (effect modiﬁcation) between the current coloni-
ation (at the time of vaccination) and the subsequent vaccine
ffect. Such an effect of current carriage on the vaccine-induced
erotype-speciﬁc antibody response has been recently shown [16].
somewhat different question relates to the potential interaction
f the vaccine effect and the current carriage (yes/no) at the time
f acquisition of (secondary) serotypes.
Protection induced by a vaccine may be heterogeneous across
ndividuals. A general discussion of the estimation of vaccine
fﬁcacy under heterogeneity is provided in an article by Hal-
oran et al. [17]. Most importantly, the account of VEcol in
he present article is based on the assumption of a leaky
accine effect, i.e. that vaccinees would beneﬁt from the vac-
ination through a reduced target serotype acquisition rate,
ather than through a portion of vaccinees being completely pro-
ected against pneumococcal colonisation (and the rest remaining
nprotected).
Ideally, investigations of the impact of vaccination on the
ynamics of colonisation should be based on longitudinal data.
owever, the complexity of analysing repeated measurement data
emains a problem. A possible role for longitudinal data would be
o validate some of the underlying assumptions about the steady
tate and ‘no efﬁcacy for duration’. In particular, if there is need
o disentangle the effects on acquisition and duration, longitu-
inal data are needed. Optimal study designs for the estimation
f acquisition and clearance rates from repeated measurement of5 non-vaccine types (see the Appendix in [1]). The VEacq against the two common
ided 90% conﬁdence intervals for the relative efﬁcacy are used. The non-inferiority
ond to the high and moderate overall rate of pneumococcal acquisition.
colonisation have been considered by Mehtälä et al. [18]. Finally, a
baseline study is useful in establishing the baseline prevalence and
serotype distribution of pneumococcal colonisation, even when
frequent longitudinal sampling is not feasible. The information
about the frequency of colonisation by serotypes included in the
current PCV can be used to interpret results from head-to-head
trials.
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Appendix A. Pneumococcal Carriage Group (PneumoCarr)
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Appendix B. Non-inferiority margins for relative efﬁcacies
The proposed method of estimation of vaccine efﬁcacy against
colonisation is based on the ability to estimate hazard ratios from
cross-sectional data under the steady-state assumption [10]. In a
head-to-head trial, the relevant hazard ratio is that for the overall
acquisition of the target serotypes (investigational vs. active con-
trol). Note that vaccine efﬁcacies cannot be estimated for either of
the vaccines, because there is no control vaccine. The reference set
of colonisation states in the odds-ratio-based estimator of the efﬁ-
cacy should exclude any serotypes common to the vaccines to be
compared.
Here we present the relation between the relative efﬁcacy and
the ratio of target-type acquisition (investigational vs. the active
control). Consider the hazard rates of target-type acquisition in
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hose receiving the investigational vaccine (V) and those receiving
he active control vaccine (U). We denote the relative efﬁcacy as
Erel =1− V/U. The relationship between the relative efﬁcacy and
he efﬁcacies of the two vaccines (VEV and VEU) is
Erel = 1 −
1 − VEV
1 − VEU
= VEU
1 − VEU
(
VEV
VEU
− 1
)
. (1)
f the active control vaccine is hypothesised to have vac-
ine efﬁcacy VEU ≈0.5, relationship (1) can be approximated as
Erel ≈VEV/VEU −1. It follows that the non-inferioritymargin posed
or the efﬁcacy ratio can be translated to a non-inferiority margin
or the hazard ratio (i.e. relative efﬁcacy). Speciﬁcally, if the efﬁcacy
f the investigational vaccine is allowed to be 100% smaller than
hat of the active control, i.e. the margin is deﬁned as
VEV
VEU
> 1 − ,
he corresponding margin for the relative efﬁcacy is −:
Erel > (1 − ) − 1 = −.
urthermore, it follows from the above argument that if VEU is
ssumed to be >0.5, a wider margin can be chosen.
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